LY-2940094

LY-2940094
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • Investigational
Identifiers
Synonyms BTRX-246040
CAS Number
ChemSpider
ChEMBL
Chemical and physical data
Formula C22H23ClF2N4O2S
Molar mass 480.96 g·mol−1
3D model (JSmol)

LY-2940094, also known as BTRX-246040, is a potent and selective nociceptin receptor antagonist which is under investigation by Eli Lilly for the treatment of major depressive disorder (MDD) and alcohol dependence.[1][2] It has demonstrated proof-of-concept clinical efficacy for depression.[3] As of 2015, it is in phase II clinical trials for both of the aforementioned indications.[1][2] However, it has more recently been reported that development for these indications has been discontinued and that the drug is now under development instead for the treatment of neurological disorders.[4]

See also

References

  1. 1 2 Dale, Elena; Bang-Andersen, Benny; Sánchez, Connie (2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs" (PDF). Biochemical Pharmacology. 95 (2): 81–97. ISSN 0006-2952. PMID 25813654. doi:10.1016/j.bcp.2015.03.011.
  2. 1 2 Yin, Xin; Guven, Nuri; Dietis, Nikolas (2015). "Opioids in Depression: Not Quite There Yet" (PDF). UK Journal of Pharmaceutical and Biosciences. 3 (1): 12–17.
  3. ↑ Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM (2015). "A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies". Neuropsychopharmacology. PMID 26585287. doi:10.1038/npp.2015.348.
  4. ↑ http://adisinsight.springer.com/drugs/800033400


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.